These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24450340)

  • 1. Cruentaren A binds F1F0 ATP synthase to modulate the Hsp90 protein folding machinery.
    Hall JA; Kusuma BR; Brandt GE; Blagg BS
    ACS Chem Biol; 2014 Apr; 9(4):976-85. PubMed ID: 24450340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
    Hall JA; Seedarala S; Rice N; Kopel L; Halaweish F; Blagg BS
    J Nat Prod; 2015 Apr; 78(4):873-9. PubMed ID: 25756299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. F1F0-ATP synthase functions as a co-chaperone of Hsp90-substrate protein complexes.
    Papathanassiu AE; MacDonald NJ; Bencsura A; Vu HA
    Biochem Biophys Res Commun; 2006 Jun; 345(1):419-29. PubMed ID: 16682002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90: Friends, clients and natural foes.
    Verma S; Goyal S; Jamal S; Singh A; Grover A
    Biochimie; 2016 Aug; 127():227-40. PubMed ID: 27295069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Evaluation of Simplified Cruentaren A Analogues.
    Dou X; Patel BA; D'Amico T; Subramanian C; Cousineau E; Yi Y; Cohen M; Blagg BSJ
    J Org Chem; 2022 Aug; 87(15):9940-9956. PubMed ID: 35894845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative approaches to Hsp90 modulation for the treatment of cancer.
    Hall JA; Forsberg LK; Blagg BS
    Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.
    Blagg BS; Kerr TD
    Med Res Rev; 2006 May; 26(3):310-38. PubMed ID: 16385472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of heat shock protein 90 chaperone function through binding of a novobiocin analog KU-32.
    Chatterjee BK; Jayaraj A; Kumar V; Blagg B; Davis RE; Jayaram B; Deep S; Chaudhuri TK
    J Biol Chem; 2019 Apr; 294(16):6450-6467. PubMed ID: 30792306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of the weak ATPase activity of human hsp90 by a client protein.
    McLaughlin SH; Smith HW; Jackson SE
    J Mol Biol; 2002 Jan; 315(4):787-98. PubMed ID: 11812147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
    Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
    Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone.
    Marcu MG; Chadli A; Bouhouche I; Catelli M; Neckers LM
    J Biol Chem; 2000 Nov; 275(47):37181-6. PubMed ID: 10945979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational dynamics of the molecular chaperone Hsp90 in complexes with a co-chaperone and anticancer drugs.
    Phillips JJ; Yao ZP; Zhang W; McLaughlin S; Laue ED; Robinson CV; Jackson SE
    J Mol Biol; 2007 Oct; 372(5):1189-203. PubMed ID: 17764690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hsp90 inhibitors identified from a library of novobiocin analogues.
    Yu XM; Shen G; Neckers L; Blake H; Holzbeierlein J; Cronk B; Blagg BS
    J Am Chem Soc; 2005 Sep; 127(37):12778-9. PubMed ID: 16159253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
    Garg G; Khandelwal A; Blagg BS
    Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hsp90 chaperone machinery: from structure to drug development.
    Hahn JS
    BMB Rep; 2009 Oct; 42(10):623-30. PubMed ID: 19874705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins.
    Ardi VC; Alexander LD; Johnson VA; McAlpine SR
    ACS Chem Biol; 2011 Dec; 6(12):1357-66. PubMed ID: 21950602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery.
    Li T; Jiang HL; Tong YG; Lu JJ
    J Hematol Oncol; 2018 Apr; 11(1):59. PubMed ID: 29699578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure, function and regulation of the hsp90 machinery.
    Li J; Buchner J
    Biomed J; 2013; 36(3):106-17. PubMed ID: 23806880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
    Brandt GE; Blagg BS
    Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor.
    Khandelwal A; Kent CN; Balch M; Peng S; Mishra SJ; Deng J; Day VW; Liu W; Subramanian C; Cohen M; Holzbeierlein JM; Matts R; Blagg BSJ
    Nat Commun; 2018 Jan; 9(1):425. PubMed ID: 29382832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.